Introduction
Tuberculosis (TB) continues to be a major global health problem with millions of new cases every year. In a 2017 global TB report, TB was the ninth leading cause of death worldwide, and for the past five years (2012) (2013) (2014) (2015) (2016) had been the leading cause of death from a single infectious agent, ranking above HIV/AIDS [1] . The prevalence of multidrug-resistant TB (MDR-TB) and extensively drug resistant TB (XDR-TB) has created a renewed demand for the discovery and development of novel TB drugs to improve the treatment outcomes.
Due to the high attrition rate in new drug development, the need for safer and more effective agents with novel mechanisms of action for the treatment of TB cannot be overemphasized [2] .
The evaluation of novel chemical scaffolds possessing desirable pharmacological profiles against M. tuberculosis and the identification of novel drug targets on M. tuberculosis are all at the forefront of new TB drug discovery and development. Remodelling the existing antibacterial drug classes and structural modifications based on natural products with antibacterial activity are undoubtedly effective approaches to discover new antituberculosis agents [3] [4] [5] . Cell wall is a functional and protective interface between external and internal environment for every living cell. Targeting the cell wall biosynthesis has been a successful strategy in TB drug development. Indolcarboxamide is a novel series of antituberculosis agent identified recently. This series targets MmpL3, a transporter of trehalose monomycolate that is essential for mycobacterial cell wall biosynthesis [6] . Two other cell wall biosynthesis drug targets, decaprenylphosphoryl-β-D-ribose 2ʹ-epimerase (DprE1) and decaprenylphosphoryl-D-2-ketoerythropentose reductase (DprE2) were also identified recently which catalyze the epimerization of decaprenylphosphorylribose (DPR) to decaprenylphosphorylarabinose (DPA), a unique precursor for the synthesis of cell-wall arabinans [7] . DprE1, as a vulnerable tuberculosis drug target due to its cell wall localization and specific to mycobacteria and actinomycete, has become an attractive target for developing more effective and safer medicines for the treatment of drug-sensitive TB as well as MDR/XDR-TB [8] [9] [10] . The first DprE1 inhibitor is nitrobenzothiazinone 1 (BTZ043) (Figure 1) [11] . Phase I clinical trials for its next generation analogue 2 (PBTZ169) with improved efficacy and safety (Figure 1 ) have been completed [1, 12] . Compound 1 serves as a suicide substrate for the reduced form of DprE1 to irreversibly inactivate the enzyme by undergoing nitro reduction to yield a nitroso species that specifically attacks the thiol side chain of the active site cysteine residue, Cys387, to form a covalent adduct [13] . The discovery of 1,3-benzothiazin-4-ones (BTZs), specifically 1 and its analogue 2, prompted further research related to the identification of potential antituberculosis agents based on electron deficient nitroaromatic structures. A series of potential DprE1 covalent inhibitors with modification on the 2 position of BTZs represented as compounds 1a and 2a was reported (Figure 1 ) [14] [15] [16] [17] . Interestingly, two compounds with relatively minor modifications to the BTZs core, benzothiazinethione (SKLB-TB1001, 3) and sulfoxide of 1 4) , maintain potent antimycobacterial activities (Figure 1) [18, 19] . The crystal structures of the DprE1 with 1 and DprE1 with 2 complex as well as the structure-activity relationships (SARs) of this series indicated that the key constituents for potent activity are the sulfur atom and carbonyl group in the thiazinone ring, a strong electron withdrawing group (CF3, CN, NO2, etc.) in the 6 position, and more importantly a nitro group in the 8 position [11, 12] . However, we noticed that the nitrogen atom in the thiazinone ring has no direct interaction with the enzyme. Inspired by the above background information, we employed bioisosteric replacement strategy to replace the nitrogen atom in the 3 position with a carbon atom and replace the sulfur atom in the 1 position with an oxygen atom aimed to identify new DprE1 inhibitors with improved physicochemical properties and safety profiles.
Herein, we report three novel structural series, benzoxazinone 5, benzothiopyranone 6 and benzopyranone 7, which maintain a CF3 group at the 6 position and a NO2 group at the 8 position (Figure 2) . After further evaluation, a benzothiopyranone compound 6b as a DprE1 inhibitor was identified as a promising preclinical candidate for the treatment of drug-resistant tuberculosis. 
Chemistry
The target compounds were synthesized following the procedure as outlined in Scheme 1.
2-Chloro-3-nitro-5-(trifluoromethyl)benzamide (8) [11] was treated with oxalyl chloride followed by an appropriate amine to afford intermediates 9a-r. Compounds 9a-r were heated in DMF in the presence of K2CO3 to give benzoxazinones 5a-r after purification by column chromatography [20] . Benzothiopyranones 6a-r were prepared by a two-steps process. The key intermediate 11 was first synthesized by treating 1-(2-chloro-3-nitro-5-(trifluoromethyl)phenyl)ethan-1-one (10) [21, 22] with NaOH and carbon disulfide (CS2) followed by methyl iodide (MeI) in DMSO [23] . The desired compounds 6a-r were obtained through nucleophilic substitution reaction of 11 with an appropriate amine. Due to the low reactivity of the leaving group methylthio, it was noted that the yield for the nucleophilic reaction between 11 and different amine could be improved by extending the reaction time. For the synthesis of the benzopyranone series, the key intermediates 13a, 13b, 13d and 13r were prepared by mixing 3-(2-chloro-3-nitro-5-(trifluoromethyl) phenyl)-3-oxopropanoic acid (12) [24] with dicyclohexylcarbodiimide (DCC) followed by an appropriate amine at room temperature [25] . Then, the above intermediates were heated in DMF in the presence of K2CO3 to give the target benzopyranone compounds 7a, 7b, 7d and 7r in good yields. 
Results and discussion

Identification of benzothiopyranones as a promising lead series
All target compounds were evaluated for their antimycobacterial activities against M.
tuberculosis H37Rv using the microplate alamar blue assay (MABA) [26] . The minimum inhibitory concentration (MIC) was defined as the lowest concentration effecting a reduction in fluorescence of ≥ 90% relative to the mean of replicate bacterium-only controls. All target compounds were further tested for their cytotoxicity against mammalian cell line (Vero cells)
as measured by the concentration required for inhibiting 50% cell growth (IC50) as compared to no-treatment control. Table 1 summarizes the biological data for 40 newly synthesized benzoxazinones, benzothiopyranones and benzopyranones. Isoniazid (INH), rifampicin (RFP), 1 and 2 were used as the reference compounds in these assays.
To explore the impact of bioisosteric replacement of the core structure, the C-2 side chains in the first batch compounds (5a-b, 6a-b and 7a-b) were kept the same as in BTZ038
(racemate of 1) and 2 (2-spiroketal and 2-piperazino moiety, respectively). As shown in Table 1 , three series displayed potent in vitro antimycobacterial activities. However, their
IC50s against Vero cell line were substantially different. When R is a spiroketal group, the benzoxazinone 5a and benzopyranone 7a showed equivalently potent antimycobacterial activities as compared to the reference compounds 1 and 2 with MICs < 0.016 μg/mL, while the benzothiopyranone 6a displayed less activity with a MIC 0.03 μg/mL. When R is a piperazino group, different level of antimycobacterial activities were observed in the following order: benzothiopyranone > benzoxazinone ≈ benzopyranone (6b MIC < 0.016 μg/mL, 5b MIC 0.159 μg/mL and 7b MIC 0.116 μg/mL). It appeared that the benzoxazinones (5a-b) and benzopyranones (7a-b) showed a certain level of cytotoxicity regardless the C-2 substitution, but benzothiopyranones (6a-b) displayed lower cytotoxicity with IC50s > 64 μg/mL. Considering that the IC50 values of 1 and 2 are both > 64 μg/mL, this result indicated the importance of the sulfur atom in position 1 not only on antimycobacterial activity but also toxicity. Due to the cytotoxicity concern, benzopyranone scaffold was dropped from further consideration.
To further understand the structure-activity and structure-toxicity relationships (SARs and STRs), the R group in position 2 of the benzoxazinone and benzothiopyranone scaffolds were systematically investigated. The lipophilicity of the synthesized compounds was estimated based on their calculated ClogP values by employing ChemDraw prediction software (ChemDraw Professional 16.0. PerkinElmer Informatics, Inc.). A series of benzoxazinones (5c-r) and benzothiopyranones (6c-r) compounds was designed and synthesized. Generally, compounds in the benzothiopyranone series had slightly higher ClogP values as compared to the corresponding compounds in the benzoxazinone series (△ClogP is about 1). As anticipated, most benzothiopyranones exhibited more potent antimycobacterial activities than the corresponding benzoxazinones. This observation is consistent with the general SAR knowledge for the benzothiazinone class -more lipophilicity (logP) correlates with better antimycobacterial activity [12] . Despite their potent antimycobacterial activities, all benzothiopyranone compounds exhibited low cytotoxicity with IC50s > 64 μg/mL, whereas the benzoxazinone compounds displayed certain level of toxicity with IC50s in the range from 3.84 to 37.85 μg/mL with the exceptions of compounds 5l and 5m. To further confirm the correlation between the cytotoxicity and the oxygen atom in position 1, we decided to re-investigate the benzopyranone series by synthesizing compounds 7d and 7r. Although both compounds 7d and 7r exhibited potent antimycobacterial activities, they all appeared to be cytotoxic with IC50 values less than 30 μg/mL. Our studies indicated that the benzothiopyranone series appears to have the desired antimycobacterial activities and cytotoxicity profiles.
Benzothiopyranone compounds substituted with a tertiary amino R (such as 6b-g containing a heterocyclic amino and compounds 6p-r containing an acyclic amino group) displayed potent antimycobacterial activities (MICs < 0.016 μg/mL) with the exceptions of compounds 6e (MIC 0.03 μg/mL) and 6g (MIC 0.054 μg/mL). However, the corresponding benzoxazinone compounds (5b-g and 5p-r) exhibited a wide range of MICs from 6.28 μg/mL to less than 0.016 μg/mL. It appears that the tertiary amino group in position 2 is better tolerated in the benzothiopyranone series than in the benzoxazinone series. 5o (MIC 0.03 μg/mL, ClogP 3.25). The volume of the substituent may also be an important factor for antimycobacterial activity, as the lipophilicity and the size of the substituent increase at the same time. M. tuberculosis possesses a thick, lipid rich cell wall, which becomes a permeable barrier for antimicrobial agents. It has been a challenge to balance the lipophilicity and the antimycobacterial activity in the field of new TB drug development. The goal of this study is to identify a new generation of BTZs derivatives with the right balance between its lipophilicity (and therefore potent antimycobacterial activity) and its pharmacokinetic profile (and therefore better in vivo efficacy). The structure of the R group in position 2 has a significant influence on the physicochemical properties of the molecule as evidenced by the improved druggability profile of compound 2 as compared to 1 [12] .
However, the tertiary amino R group in position 2 in the benzothiopyranone series seems to have a minimum influence on the antimycobacterial activities of the investigated compounds.
It appears that there are more opportunities to identify better compounds by optimizing the side chain R in position 2 of the benzothiopyranone series to deliver a potential drug candidate for the treatment of TB. 
Evaluation of Compound 6b as a potential drug candidate for the treatment of TB
Metabolic Stability and Antimycobacterial Activity against Clinical Isolates of M. tuberculosis of Selected Benzothiopyranones
One significant challenge associated with the benzothiazinone series is its poor pharmacokinetic (PK) profile. Microsomal instability was identified as a possible liability of BTZs such as 2 showed medium clearance values when incubation with human or mouse microsomes [12] . To identify the metabolic liabilities of the novel benzothiopyranone series, eight compounds (6a-f, 6p and 6r) with a variety of side chain R and potent antimycobacterial activities together with the reference compound 2 were evaluated for their stability in mouse liver microsome (MLM) and human liver microsome (HLM) ( Table 2 ). As shown in Table 2 , compounds with relative rigid cyclic amino side chain R (6a-f) exhibited medium to good stability in MLM or HLM with the exception of 6d that was unstable in MLM. However, compounds 6p and 6r showed low microsomal stability possibly due to the flexible acyclic amino side chain R. The side chain R could play a major role on influencing the PK profile. Further medicinal chemistry effort by increasing the size of the R group and therefore sterical hinderance could potentially further improve microsomal stability.
Encouragingly, compounds 6b, 6c, 6e and 6f showed similar MLM stability as that of 2, but better stable than 2 in HLM. Based on their good liver microsome stability, compounds 6b and 6e were further tested against two XDR-TB clinical isolates ( Table 3) . Cytotoxicity against mammalian cells was also evaluated against HepG2 cells. Selectivity index (SI) was subsequently calculated (Table 3) . Inspiringly, the two new compounds together with the reference control 2 retained potent activities against XDR-TB strains and also displayed very low cytotoxicity with high IC50 values of > 64 μg/mL against HepG2 cells as compared to the reference control 2. Of particular interest, compound 6b exhibited potent activity against XDR-TB strains with MIC less than 0.002 μg/mL and excellent SI. 
Preliminary ADME/T Studies on Compound 6b
Based on the promising biological results described above, selected ADME/T studies were conducted on compound 6b to investigate its drug-like properties ( Table 4 ). As presented in Table 4 , compound 6b did not inhibit cytochrome P450 enzymes (CYP 1A2, CYP 2C9, CYP 2C19, CYP 2D6 and CYP 3A4) with IC50s > 50 μM, suggesting a low potential for drug-drug interactions. In order to further evaluate its metabolic stability, compound 6b along with the reference compound 2 were investigated for their hepatocyte stability in mouse and human species. To our delight, compound 6b exhibited superior stability both in mouse and human hepatocyte with much longer t1/ 2 and lower intrinsic clearance (Clint) compared to the reference compound 2. Low inhibition of hERG (IC50 > 30 μM) suggests low risk for blocking the cardiac potassium channel and causing QT prolongation. A preliminary in vivo tolerability study was carried out in mice with a single dose at 2 g/kg. All animals survived after oral administration followed by a 7-day observation. Thus far, all the results supported compound 6b to be worth of further investigation. 
Pharmacokinetic Studies on Compound 6b
Pharmacokinetic studies on compound 6b were performed in male Balb/c mice, following single oral and intravenous dose administration ( Table 5 ). As shown in Table 5 , except relatively low bioavailability (13.1%), compound 6b displayed an excellent PK profile as reflected by high plasma exposure (AUC0−∞ = 1695 ng·h/mL), and long elimination half-life (t1/ 2 = 7.25 h) after oral administration. It is worth to indicate that the reference compound 2 exhibited short half-life with t1/ 2 = 1.85 h when dosed at 25mg/kg in Balb/c mice as reported [12] . These results indicated that compound 6b had promising PK properties to move into in vivo efficacy studies in animal models. 
In vivo Efficacy Study on Compound 6b in Mouse Model of TB
Lastly, the preliminary in vivo efficacy evaluation of compound 6b was conducted in a murine model of acute infection with M. tuberculosis H37Rv. Compound 6b was orally administered at 100 mg/kg, whereas the positive control drug isoniazid (INH) was given at 25 mg/kg. The same formulation 0.5% carboxymethylcellulose (CMC) in water was used for all tested compounds. As exhibited in Table 6 , compound 6b appeared highly active after 3
weeks treatment, which resulted in a significant reduction of M. tuberculosis colony-forming unit (CFU) in lungs by 5.4 logs as compared to the untreated control group. Encouragingly, compound 6b at 100 mg/kg demonstrated similar bactericidal activity compared to INH (25 mg/kg). Further evaluation of this promising compound is currently under way to fully assess its potential for further development for the treatment of MDR-TB and XDR-TB. 
DprE1 Inhibition Assay
In order to confirm the inhibition of M. tuberculosis by the benzothiopyranone derivatives via DprE1 inhibition, we measured the inhibitory activities of the representative compounds 6a, 6b, 6e and positive controls 1, 2 against DprE1. The results demonstrate that the selected benzothiopyranone compounds with potent antimycobacterial activities and diversified side chains displayed potent DprE1 inhibition with IC50 values from 0.63 to 4.53 µM, which exhibited the similar mechanism against M. tuberculosis as compared to the benzothiazinone controls 1 and 2 ( Table 7 ). 
Conclusion
Antimycobacterial drug target DprE1 and its inhibitor benzothiazinone series represent the new trend in TB drug discovery. Benzothiopyranone compound 6b, obtained by scaffold morphing from benzothiazinones, has been identified as a promising TB drug candidate with potent activity, low toxicity and acceptable PK properties. Extensive SAR studies provide weeks treatment, which is equivalent to that of the first-line TB drug INH. Especially, the preliminary ADME/T data displayed that compound 6b owned potential druggability profiles.
Additionally, in a PK study in mice, compound 6b exhibited a long half-life (t1/ 2 = 7.25 h) after oral administration, therefore it has the potential to be given at a lower dose and less frequency to improve patient compliance. With the encouraging data, compound 6b which exhibits good inhibitory activity against DprE1 has been selected as a potential drug development candidate for the treatment of TB. Further evaluation including combination study and deep druggability of compound 6b is under way to fully assess its potential as a new agent to treat DR-TB.
Experimental
Chemistry
General experimental information
All the solvents and chemicals were obtained from commercial sources and used without further purification. TLC was performed on silica gel plates (GF254) atmosphere of argon. After filtration and concentration under reduced pressure, the residue was purified by flash column chromatography (EtOAc: PE = 1:4) to afford the target compounds 5a-r. [1, 3] oxazin- 4-one (5a [1, 3] oxazin- 4-one (5d [1, 3] oxazin- 4-one (5f piperazin-1-yl)-6-(trifluoromethyl)-4H-benzo[e] [1, 3] oxazin- 4-one (5g [1, 3] oxazin- 4-one (5n [1, 4] [1, 3] [1, 3] 5. [1, 3] oxazin- 4-one (5q 156.9 (156.2), 149.3, 148.6, 136.4, 131.1, 128.2, 127.1, 126.9, 122.2 (q, 1 JF, C = 271 Hz), 121.4, 120.3 (120.2), 111.8, 111.4, 111.1 (111.0), 56.0, 55.9, 53.5 (53.1), 36.4 (34.2) . HRMS (ESI): m/z [M+H] + calcd for C19H17F3N3O6, 440.1064; found, 440.1049. 5.1.2.18. 2-(((2,3-Dihydrobenzo[b] [1, 4] [1, 3] oxazin- 4-one (5r 7, 143.8, 143.7, 136.3, 130.9, 127.6 (127.5) The degassed isopropanol (5 mL) was added. The tube was flushed with argon, capped, and heated at 140 °C for 12-48 h. After cooling to room temperature, the reaction mixture was concentrated in vacuum, and the residue was purified by column chromatography (EtOAc: PE = 1:2) to give the target compounds 6a-r. 9, 156.0, 144.4, 134.0, 133.5, 131.4, 128.9 (q, 2 JF, C = 35 Hz), 125.3, 122.7 (q, 1 JF, C = 267 Hz), 106. 2, 100.2, 72.5, 70.9, 46.5, 36.0 (34.8), 18.4. HRMS (ESI) : m/z
[M+H] + calcd for C18H18F3N2O5S, 431.0890; found, 431.0879. 1.3.2. 2-(4-(Cyclohexylmethyl)piperazin-1-yl) 9, 159.6, 144.4, 134.0, 133.7, 131.5, 128.9 (q, 2 8, 159.4, 144.4, 133.9, 133.7, 131.5, 128.9 (q, 2 JF, C = 35 Hz), 125.3, 122.6 (q, 1 JF, C = 271 Hz), 99. 8, 60.2, 55.1, 54.2, 50.0, 48.2, 35.6, 32.0 (31.7) , 26.7, 26.2 (26. piperazin -2-one (6d 2H ). 13 C NMR (100 MHz, CDCl3) δ: 176. 5, 163.4, 157.6, 144.3, 133.6, 133.4, 131.8, 129.3 (q, 25.7 1.3.5. 2-(4-Benzylpiperazin-1-yl) 9, 159.6, 144.4, 137.0, 134.0, 133.6, 131.5, 129.1, 128.8, 128.5, 127.6, 125.4, 122.6 (q, 1 (brs, 1H), 2.32 (t, J = 9.2 Hz, 1H), 1.26 (d, J = 6.0 Hz, 3H). 13 C NMR (100 MHz, CDCl3) δ:
5.
176. 8, 159.3, 144.4, 137.8, 133.9, 133.6, 131.5, 129.0, 128.9 (q, 2 1, 171.0, 159.4, 144.4, 139.4, 133.8, 133.5, 131.7, 129.2 (q, 2 4, 158.6, 143.8, 134.5, 134.2, 131.8, 128.7, 125.2, 122.6 (q, 1 4, 157.3, 144.6, 137.6, 134.9, 133.4, 129.8, 129.6, 126.7 (q, 2 7, 157.7, 143.8, 135.2, 134.4, 134.0, 131.9, 129.3, 129.1, 128.7, 127.8, 125.4, 122.6 (q, 1 amino)- 8-nitro-6-(trifluoromethyl)-4H-thiochromen -4-one (6n 2, 159.8, 149.5, 149.3, 143.9, 134.1, 133.4, 131.7, 129.1 (q, 2 JF, C = 35 Hz), 127. 2, 125.4, 122.5 (q, 1 JF, C = 271 Hz), 120.7, 111.4, 111.2, 98.7, 56.0, 55.9, 48.6 [1, 4] dioxin-6-yl)methyl)amino)- 8-nitro-6-(trifluoromethyl)-4H-thiochromen-4-one (6o target compounds 7a, 7b, 7d, 7r . To a magnetically stirred solution of intermediate 13 (0.2 mmol) in dry DMF (2 mL) was added potassium carbonate (28 mg, 0.2 mmol) . The contents were heated at 110 °C for 1 h under an atmosphere of argon. After filtration and concentration under reduced pressure, the residue was purified by flash column chromatography (MeOH:CH2Cl2 = 1:100) to afford the target compounds 7a, 7b, 7d, 7r. 161.4, 147.9, 137.2, 129.0, 126.8 (q, 2 JF, C = 35 Hz), 126.0, 125.5, 122.5 (q, 1 JF, C = 271 Hz), 106. 1, 86.9, 72.5, 70.9, 43.8 (43 piperazin-1-yl)- 8-nitro-6-(trifluoromethyl)-4H-chromen-4 -one (7b 9, 161.7, 147.8, 137.3, 129.0, 126.6, 126.1, 125.4, 122.5 (q, 1 JF, C = 272 Hz), 86.8, 65.2, 52.6, 45.3, 35.0, 31.7, 26.7, 26. benzoyl) -4-(thiazol-2-yl) 7.30-7.27 (m, 4H), 7.19-7.15 (m, 1H) . 7.36-7.30 (m, 3H), 7.22-7.19 (m, 2H), 4.42-4.38 (m, 2H) . phenyl)- 3-hydroxy-1-(2-methyl-1,4-dioxa-8 -azaspiro[4.5]decan-8-yl)prop-2-en-1-one (13a phenyl)-N-( (2,3-dihydrobenzo[b] [1, 4] dioxin-6-yl)methyl) -3-hydroxy-N-methylacrylamide (13r hERG channel current was carried out following the standard protocol as described previously [27] . HEK 293 cells were stably transfected with human Ether-à-go-go related gene (hERG) channel. The voltage-gated hERG potassium channel current was recorded at room temperature (25 °C) from randomly selected transfected cells under whole-cell manual patch clamp systems equipped with EPC10 USB (HEKA) or Multiclamp 700B amplifier (Molecular Devices), while electrical data was digitalized by Digidata1440A with sampling frequency at 10 kHz using Patchmaster or pClamp10 respectively. hERG current inhibition in presence of 5 concentrations, including 30, 10, 3.0, 1.0 and 0.3 µM, was tested for IC50 determination. Dofetilide was also included as a positive control to ensure the accuracy and sensitivity of the test system. All experiments were performed in duplicate for IC50 determination. The compound with IC50 > 30 μM was generally considered to have a lower potential for hERG K + channel inhibition.
5.2.7.
Acute toxicity study. Compound 6b was screened in vivo with a single dose in Balb/c mouse (female) weighing 18 to 21 g with ten mice. The number of mice which survived after an oral administration of a single dose at 2 g/kg, followed by a 7-day observation, was recorded. week. The treatment period was 3 weeks. Mice were sacrificed the day after the last day of treatment, lungs removed, homogenized, and serially diluted in 10-fold steps in HBSS. One hundred μL were spread on 7H11 agar in duplicate. The plates were incubated at 37 °C for 3
weeks. Data are expressed as the log10 (and as log10 reduction) provided by a given dose of the compound against the growth of the organism in the untreated control group. Mean log10 values were calculated from bacterial burden counts. Student's t test was used to compare means between the test and control groups. A P value of ≤0.05 was considered significant.
5.2.10.
In vitro DprE1 inhibition assay. DprE1 assays were performed as described previously [28] . Briefly, a 10 μL reaction was performed at 30 C in 384-well black plates in buffer containing 50 mM Hepes, pH 7.5, 100 mM NaCl, 1.5% (v/v) DMSO, 100 μM Tween-20, 2 μM FAD, and 50 μM resazurin, with variable concentrations of FPR and DprE1.
Reactions were monitored by following an increase in fluorescence intensity (λex = 530 nm, λem = 595 nm) associated with the formation of resorufin. For inhibition studies, DprE1 (1 μM) was measured with the resazurin assay with 1 mM FPR in the presence of different inhibitor concentrations. The IC50 values were obtained by plotting the initial velocities with inhibitor concentration. The IC50 values calculated using the software program GraphPad
